NIBEC
Public · 2 known investors
Nibec is a South Korean biotech company that develops peptide-based therapeutics and dental biomaterials, including bone graft materials, periodontal tissue regeneration products, tooth-whitening agents, and drug-delivery platforms. It supplies materials to global implant and pharmaceutical companies and pursues clinical development of treatments for conditions such as pulmonary fibrosis and inflammatory bowel disease.
Also known as (주)나이벡 · NIBEC Co., Ltd. · 나이벡
Investors · 2
Company profile
researched Aug 2026NIBEC Co., Ltd. (나이벡) is a South Korean biotechnology company working across pharmaceuticals and medical devices, with a focus on peptide technology and tissue regeneration. Its business areas include oral care products (tooth whitening agents, tooth desensitizers, dental conditioners), biomaterials for tissue regeneration (bone graft materials, barrier membranes, intraoral products, resorbable collagen membrane matrices and growth-factor enhanced matrices), cosmetics, and bio-fusion peptide products combining functional peptides with regenerative materials. The company also markets prescription products for periodontal disease and a companion-animal healthcare line.
On the therapeutics side, NIBEC develops peptide-based candidates for fibrosis, obesity and oncology. Disclosed assets include NP-201 (in Phase 1b/2a for ulcerative colitis and positioned as an anti-fibrotic program), NP-201-401, Regenotide (an anti-obesity candidate described as increasing muscle mass, reducing fat accumulation and addressing MASH), NP-501 for renal carcinoma, NIPEP-OSS (a collagen-binding osteogenesis-stimulating peptide in Phase 1 for osteoporosis), and mKBscFv-CPP, a preclinical KRAS degrader. The company reports a peptide library of more than 800 compounds and more than 12 ongoing pipeline programs, and cites an AI-assisted discovery platform, TOPscovery.
NIBEC also positions itself as a peptide manufacturing and process-development partner, citing solid-phase peptide synthesis (SPPS) capability, analytical infrastructure including RP-HPLC and MALDI-TOF/MS, and dedicated peptide GMP production lines designed to prevent cross-contamination.
Business model
NIBEC combines sales of medical devices and biomaterials (bone grafts, collagen membranes, oral care and periodontal products, companion-animal regenerative products) with contract peptide process development and GMP manufacturing services for commercial pharmaceuticals, and pursues out-licensing and co-development partnerships for its internal peptide drug pipeline.
Revenue derives from the development, manufacture and commercialization of medical products and supplies across oral care, tissue-regeneration biomaterials, cosmetics and bio-fusion peptide lines, supplemented by peptide manufacturing/process-development partnerships and sought-after licensing arrangements for pipeline assets.
Traction
The company reports more than 30 countries of regulatory approval/market entry, a peptide library exceeding 800 compounds and more than 12 active pipeline programs. Clinical activity includes a Phase 1b/2a trial of NP-201 acetate injection in healthy volunteers and mild-to-moderate active ulcerative colitis patients (started November 2024), a multicenter confirmatory trial of PeptiCol EZgraft for extraction socket preservation (started January 2025), and a completed international post-market clinical follow-up study of OCS-B and Regenomer in socket preservation.
Latest developments
In June 2026 NIBEC presented its NP-201 global clinical strategy and follow-on pipeline assets (Regenotide, 401, 501, 701) at BIO USA 2026, where it stated it was seeking strategic collaborations and licensing partners and pointed to planned Phase 2 initiation for NP-201 and IND-enabling work for Regenotide, with the next major catalysts expected in the first half of 2027. In July 2026 the company announced Brazilian product approval for OCS-B Collagen as part of an expansion into the Latin American medical device market. Next-generation products OssGen-X15 and Pepticol EZgraft are in US FDA pre-submission.
▸Full profile — market position, technology, go-to-market, geography, history
Market position
NIBEC is a KRX-listed (ticker 138610) biotechnology company with roughly 100-250 employees, operating in both the therapeutic peptide and dental/regenerative biomaterials segments.
NIBEC combines proprietary functional-peptide chemistry with regenerative biomaterials, applying the same peptide platform across drug candidates, dental and tissue-regeneration devices, and animal health products, and pairs this with in-house SPPS and peptide-dedicated GMP manufacturing.
Technology
The company's core platform is PEPTARDEL (펩타델), a peptide drug-delivery technology offered in three configurations: PEPTARDEL-T for targeted cell-membrane penetration with prolonged activity, PEPTARDEL-S for controlled sustained release lasting from seven days to three months, and PEPTARDEL-O for oral formulations that extend intestinal residence time and stabilize blood drug concentrations. NIBEC also cites an AI-assisted discovery platform called TOPscovery, a library of over 800 peptides, functional-peptide fusion biomaterials, and SPPS-based synthesis with RP-HPLC and MALDI-TOF/MS analytics in peptide-dedicated GMP facilities.
Go-to-market
The company sells regulated medical devices and pharmaceuticals through international market registrations, pursues regulatory clearances in multiple jurisdictions, and uses industry partnering venues such as the BIO International Convention to seek strategic collaborations and out-licensing for its pipeline and TOPscovery platform.
Dental and surgical practitioners using bone graft, collagen membrane and periodontal products; pharmaceutical companies seeking peptide process development and GMP manufacturing; potential licensing and co-development partners for therapeutic assets; and the veterinary/companion-animal healthcare segment.
Geography
Headquartered in South Korea, with corporate presence cited in Seoul and in Jincheon-gun. The company reports regulatory approvals and market entry in more than 30 countries, including European MDR, US FDA and China NMPA clearances, product registration in Brazil, and stated plans for Latin American market expansion in 2026.
History
NIBEC was founded on February 20, 2004 in South Korea and is listed on the Korea Exchange under ticker 138610. It has expanded from oral care and tissue-regeneration biomaterials into bio-fusion peptide products, cosmetics, companion-animal healthcare and peptide therapeutics development.
Compiled by commissioned research from 7 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 6
launches, deals, and filingsNIBEC announced it obtained Brazilian marketing approval for OCS-B Collagen, expanding its push into the Latin American medical device market.
The company disclosed its NP-201 global clinical strategy and results for follow-on pipeline assets including Regenotide, 401, 501 and 701.
NIBEC gave a company presentation at BIO 2026, seeking strategic collaborations and licensing opportunities for its peptide therapeutics portfolio and AI-assisted TOPscovery platform.
Multicenter, open-label, randomized confirmatory trial evaluating the safety and efficacy of periodontal tissue-inducing photoresponsive PeptiCol EZgraft in extraction socket preservation versus Regenomer; sponsored by NIBEC.
Randomized, double-blind Phase 1b/2a study of subcutaneous NP-201 acetate injection in healthy adults and patients with mild-to-moderate active ulcerative colitis; sponsored by NIBEC.
Randomized, controlled international multicenter post-market clinical follow-up study in socket preservation; sponsored by NIBEC; listed as completed.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
In the news
▸Research sources · 7
primary sources listed
- NIBECnibec.co.kr · web
7 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does NIBEC do?
- South Korean peptide biotechnology company developing regenerative drug candidates, dental biomaterials and peptide drug-delivery platforms.
- Who are NIBEC's investors?
- NIBEC's investors include Hyundai Venture Investment Corporation, Kiwoom Investment.